ArticleRevista brasileira de hematologia e hemoterapia
Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges.
Article in Revista brasileira de hematologia e hemoterapia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Acquired Hemophilia A Revealing Occult Splenic Marginal Zone Lymphoma.The American journal of case reports · 2026Article
- Splenic Marginal Zone Lymphoma as a Vascular-Appearing Mass in a Patient With Sustained Virologic Response to Hepatitis C Therapy.The American journal of case reports · 2026Article
- Article
- Splenic marginal zone lymphoma associated with chronic inflammatory demyelinating polyradiculoneuropathy: a case report.Journal of medicine and life · 2025Article
- Recurrent Acquired Angioedema as a Heralding Sign of Splenic Marginal Zone Lymphoma Recurrence.Cureus · 2025Article
- Clinical and Diagnostic Challenges in Primary Splenic Lymphomas: When is Splenectomy Necessary to Differentiate SMZL from DLBCL?European journal of case reports in internal medicine · 2025Article
- Splenic Marginal Zone Lymphoma in a Patient With Antiphospholipid Syndrome Treated With Rituximab: A Case Report.Cureus · 2024Article
- Marginal zone lymphoma with severe rashes: A case report.World journal of clinical cases · 2024Article
- Splenic Lymphomas: A Tertiary Care Center Experience and Review of Literature.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023Article
- Article
- Management of Marginal Zone Lymphoma: A Canadian Perspective.Current oncology (Toronto, Ont.) · 2023Review
- Incidental Splenic Marginal Zone Lymphoma With Extreme Macrocytosis After Hydroxyurea Use: A Case Report.Cureus · 2023Article
- The Diagnostic Dilemma of Splenic Non-Hodgkin's Lymphoma and Splenic Abscess: A Narrative Review.Cureus · 2022Review
- Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (VCurrent oncology (Toronto, Ont.) · 2022Article
- Massive splenomegaly requiring differential diagnosis of hematologic malignancies.Clinical case reports · 2022Article
- Characterization of spleen and lymph node cell typesFrontiers in molecular neuroscience · 2022Article
- Marginal zone lymphoma: present status and future perspectives.Haematologica · 2022Article
- Advances in the Treatment of Hairy Cell Leukemia Variant.Current treatment options in oncology · 2022Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical course. As a rare disease, with no randomized prospective trials, there is no standard of care for SMZL so far. Splenectomy has been done for many years as an attempt to control disease, but nowadays it has not been encouraged as first line because of new advances in therapy as rituximab, that are as effective with minimal toxicity. Facing these controversies, this review highlights advances in the literature regarding diagnosis, prognostic factors, treatment indications and therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.